Anxiety-related research
Limited Human Evidence
Some human reports exist. Not an FDA-approved anxiolytic.
Also known as TP-7
Synthetic tuftsin-derived heptapeptide studied for anxiolytic and nootropic hypotheses, including work outside the U.S. Not FDA-approved.
Selank is a synthetic analog related to tuftsin. It has been investigated for effects on anxiety-related and immune-related signaling, including intranasal research in some countries. It is not FDA-approved, and evidence should not be generalized from small or non-U.S. programs without reading primary studies.
Selank is a short lab-made peptide related to an immune fragment called tuftsin.
It is often described as anxiolytic without heavy sedation in research summaries. Those descriptions are not FDA labeling.
Researchers think Selank may change brain-chemical and immune signals involved in stress and anxiety, based on experimental and some human research outside typical U.S. drug pathways. That is still investigational from an FDA perspective.
Proposed mechanisms include modulation of monoamine metabolism, GABA-related signaling, and expression of genes linked to serotonin and BDNF in certain models. These remain hypotheses pending rigorous, generalizable trials.
Step 1
Peptide
Selank (tuftsin analog)
Step 2
Proposed targets
CNS transmitter and immune-modulatory pathways (research hypotheses)
Step 3
Pathway
Stress/anxiety-related signaling in experimental and limited human work
Step 4
Observed research effect
Anxiolytic hypotheses; not FDA-established
Some human reports exist. Not an FDA-approved anxiolytic.
Human studies have been reported in some literature, including anxiety-related research. Quality, size, and independent replication vary. This page does not treat those reports as U.S. established care.
Animal and molecular work on monoamine, GABA-related, and immune gene-expression hypotheses exists in the literature.
No sourced study cards have been attached yet. Information not sufficiently established at the study-card level.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Non-U.S. authorization, if any, is not automatically U.S. evidence.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Discovery
complete
Tuftsin analog design.
Human studies
in progress
Limited and region-specific literature.
Regulatory status
not started
Not FDA-approved.
No.
Neurological Research
Synthetic ACTH fragment analog studied as a nootropic/neuroprotective candidate in some countries. Not FDA-approved.
View peptide →